कंपनी का अवलोकन
Auna SA operates as a comprehensive healthcare service provider with a strategic footprint spanning hospitals, clinics, and prepaid healthcare plans across Mexico, Peru, and Colombia. The company also offers specialized dental and vision insurance plans alongside the retail sale of medicines, serving a diverse patient demographic in Latin America. This entity functions within the Healthcare sector, specifically categorized under the Medical Care Facilities industry, which implies a focus on direct patient care delivery and health insurance administration. With a market capitalization of $442.60M and annual revenue of $4.39B, the company demonstrates significant operational scale within its regional markets. While specific employee count data is not publicly disclosed in the available records, the revenue magnitude suggests a substantial organizational structure required to manage hospital networks and insurance portfolios. The market cap figure of $442.60M indicates a mid-to-large cap positioning relative to peers in the medical care facilities space, reflecting investor confidence in its established presence in three distinct countries. The annual revenue of $4.39B underscores the company's capacity to generate substantial top-line income, positioning it as a key player in the Latin American health services ecosystem.
वित्तीय स्वास्थ्य
The financial statements for the trailing twelve months reveal a revenue stream of $4.39B, accompanied by a net income of $97.61M and an EBITDA of $819.49M. The substantial disparity between the $4.39B revenue and the $97.61M net income highlights a complex cost structure where operating expenses, including cost of goods sold, salaries, and administrative costs, absorb the majority of the generated sales. Free cash flow stands at $47.48M, which represents the cash remaining after capital expenditures, indicating the company's capacity to fund operations, repay debt, or pursue strategic initiatives without external financing. Gross margin is reported at 37.9%, suggesting that the company retains more than a third of sales revenue after covering direct costs associated with providing healthcare services and medicines. Operating margin sits at 12.8%, reflecting the efficiency of core business operations before interest and taxes, while the profit margin of 2.2% illustrates the final bottom-line profitability after all expenses are deducted. The company holds $365.00M in cash against total debt of $3.94B, resulting in a debt-to-equity ratio of 223.10, which indicates a highly leveraged balance sheet rather than a conservative stance. Despite the high leverage, the current ratio of 1.11 suggests that the company maintains sufficient current assets to cover its short-term liabilities, albeit with limited liquidity buffer. Return on Equity is calculated at 6.5%, and Return on Assets stands at 5.4%, metrics that collectively reveal the effectiveness of management in generating returns on shareholders' investments and the total asset base respectively.
मूल्यांकन आकलन
The valuation metrics present a trailing P/E ratio of 15.74 and a forward P/E of 5.25, indicating a significant divergence between current earnings performance and expected future earnings potential. This wide gap between the trailing and forward P/E implies that the market expects a sharp increase in earnings or a substantial re-rating of the stock price in the coming periods. The price-to-book ratio is 0.98, suggesting that the market values the company at slightly less than its net asset book value, which often occurs in capital-intensive industries or those facing high leverage. The price-to-sales ratio of 0.10 is extremely low relative to the $4.39B revenue base, signaling that the stock is priced very cheaply relative to its sales volume. The EV/EBITDA multiple of 5.11 further supports a low valuation premise when considering the enterprise value relative to cash flow generation. Regarding price metrics, the stock has traded between a 52-week low of $4.46 and a 52-week high of $7.50, providing a clear range for volatility analysis. The beta value of 1.64 indicates that the stock price is significantly more volatile than the broader market, moving approximately 64% more than the market index during periods of fluctuation. These valuation and volatility metrics suggest a stock with high risk characteristics but potentially attractive entry points based on historical trading ranges.
Growth & Income
Revenue growth year-over-year is recorded at 6.6%, while earnings growth for the trailing twelve months is listed as N/A due to the specific reporting constraints of the available data. The absence of reported earnings growth figures prevents a direct comparison of earnings acceleration relative to revenue expansion, though the 6.6% revenue growth demonstrates consistent top-line expansion. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that all net income is retained within the business rather than distributed to shareholders. This retention strategy suggests management prioritizes reinvesting earnings into growth initiatives, debt reduction, or capital investments to expand its hospital and clinic network in Mexico, Peru, and Colombia. The overall growth and income profile is characterized by steady revenue expansion in a leveraged capital structure without reliance on dividend income for investors.